{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-26-000061","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2026-08-06T20:10:29+00:00","discovered_at":"2026-08-06T20:11:31.330108+00:00","generated_at":"2026-08-06T20:13:57.132516+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zentalis Q2 2026 cash $174.6M; DENALI Part 2 topline readout expected 1H 2027","bullets":["Cash, cash equivalents and marketable securities of $174.6M as of June 30, 2026, providing runway into late 2027.","R&D expenses $35.2M (up $7.6M YoY) driven by $7.0M milestone payment for ASPENOVA Phase 3 start and increased clinical costs.","Total operating expenses $44.4M for Q2 2026 vs $36.1M in Q2 2025.","FDA Type D meeting: no objection to azenosertib 400mg QD 5:2 dose for Cyclin E1-positive PROC; accelerated approval strategy intact.","DENALI Part 2 enrollment complete in Parts 2a/2b; Part 2c enrolling; integrated topline readout expected 1H 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-26-000061","json":"https://secwatch.observer/filing/0001725160-26-000061.json","markdown":"https://secwatch.observer/filing/0001725160-26-000061.md","text":"https://secwatch.observer/filing/0001725160-26-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000061/0001725160-26-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516026000061/zntl-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:13:57.132516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}